États-Unis · Bourse & Finance · Morningstar

Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia

Publié par Morningstar · États-Unis il y a 21 h

SHANGHAI, Oct. 17, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta Bio"), a company spun out of the in vivo CAR-T platform of Beijing Grit…

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia

À lire aussi

Replit is no longer working with Anthropic, CEO says

My 2 friends and I had babies within 3 weeks of each other after 25 years of friendship. Our group chat became a lifeline.

Weak Links Start to Show in A.I. Borrowing

Alberta has the world’s fourth-largest oil reserves and sends 90% of its crude exports to the U.S. — It will vote on a first step to leaving Canada

Bulls vs. Bears: Is CoreWeave the canary in AI coalmine?

Crypto Super PAC Fairshake Pours Millions More Into Defeating Sherrod Brown

Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia

Partager

À lire aussi

Replit is no longer working with Anthropic, CEO says

My 2 friends and I had babies within 3 weeks of each other after 25 years of friendship. Our group chat became a lifeline.

Weak Links Start to Show in A.I. Borrowing

Alberta has the world’s fourth-largest oil reserves and sends 90% of its crude exports to the U.S. — It will vote on a first step to leaving Canada

Bulls vs. Bears: Is CoreWeave the canary in AI coalmine?

Crypto Super PAC Fairshake Pours Millions More Into Defeating Sherrod Brown